NUCLEAR ANTIGEN MARKERS IN HUMAN BLOOD CELLS

髓样细胞核分化抗原（MNDA）是一种m/r 55，000蛋白，特异性表达于人类骨髓 细胞 MNDA存在或不存在的意义 在人类骨髓细胞生长和分化异常中 将建立。 这些结果将与 标准诊断测试和能力分析的结果 异常造血细胞在体外分化， 不添加诱导剂。 核心是一个控制 细胞中存在过度分化，因此， 造血细胞核状态的标记物可能导致 在血液病理学上更可靠的诊断。 一项长期 该项目的目标是促进使用新的 治疗骨髓细胞生长异常的方法 分化 单克隆抗体和免疫印迹 技术将用于调查物理特性， MNDA的结合特性。 这些抗体也将 用于显微注射实验和定位 在超微结构水平上的MNDA。 MNDA的基因 将被克隆，序列信息将用于 与其他蛋白质同源。 MNDA是一个低 表达细胞中蛋白质丰度和 重组蛋白将是必要的， 特征和功能分析。 附加信息 功能将通过开发 合适的基因构建体， 在正常情况下不表达 MNDA和抑制MNDA在表达中的表达 细胞 MNDA基因的探针将用于检查 染色体定位的基因，并阐明调控 其在白血病细胞系和人造血细胞系中的表达 肿瘤。 MNDA的发现提供了一个独特的 有机会利用细胞特异性核 蛋白质作为人类骨髓细胞的标志物，并作为一种工具， 研究可能在细胞核中起作用的机制 在正常和异常骨髓细胞分化期间。

The myeloid cell nuclear differentiation antigen (MNDA) is an m/r 55,000 protein that is specifically expressed in human myeloid cells. The significance of the presence or absence of the MNDA in abnormalities of human myeloid cell growth and differentiation will be established. These results will be correlated with the results from standard diagnostic tests and analysis of the ability of abnormal hematopoietic cells to differentiate in vitro with or without added inducers. The nucleus is a location where control over differentiation exists in the cell; therefore, the development of markers of the nuclear status of hematopoietic cells could lead to more reliable diagnosis in hematopathology. A longterm objective of the project is to contribute to the use of new approaches to treating abnormalities of myeloid cell growth and differentiation. Monoclonal antibodies and immunoblotting technology will be used to investigate physical characteristics and the binding properties of the MNDA. These antibodies will also be used in microinjection experiments and in the localization of MNDA at the ultrastructural level. The gene(s) for the MNDA will be cloned and the sequence information will be used to establish homology to other proteins. The MNDA is a low abundance protein in expressing cells and the expression of recombinant protein will be necessary for complete characterization and functional analysis. Additional information on function will be obtained through the development of appropriate gene constructs that will make it possible to express the MNDA protein in cells that do not normally express the MNDA and to inhibit the expression of the MNDA in expressing cells. Probes for the MNDA gene will be used to examine the chromosomal location of the gene and elucidate the regulation of its expression in leukemic cell lines and human hematopoietic neoplasms. The discovery of the MNDA provides a unique opportunity to exploit the presence of a cellspecific nuclear protein as a marker of human myeloid cells and as a tool to investigate mechanisms that may be operating in the nucleus during normal and abnormal myeloid cell differentiation.